|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 55.85 USD | +3.50% |
|
+1.97% | +27.42% |
| 07-02 | Exelixis Faces Balanced Risk-Reward Ahead of Key Catalysts, UBS Says | MT |
| 07-02 | UBS Adjusts Price Target on Exelixis to $52 From $43, Maintains Neutral Rating | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| EXELIXIS, INC. | Bio Therapeutic Drugs | +3.50% | +1.97% | +27.42% | +21.02% | +205.86% | 14.04B |  | | |
- Stock Market
- Stocks
- EXEL Stock
- Charts Exelixis, Inc.
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
